Enos C. Kline

Enos C. Kline

Auto-generated profile, based on publicly available information

Enos C. Kline

Department of Bioengineering, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Science Advances
Verified
Journal Article
Open access
NPNuttada Panpradist
Nuttada Panpradist
EKEnos C. Kline
Enos C. Kline
RARobert G. Atkinson
Robert G. Atkinson
MRMichael Roller
Michael Roller
QWQin Wang
Qin Wang
BLBarry Lutz
Barry Lutz
A unique four-plexed RT-LAMP test kit operated by health workers can provide faster, more sensitive results than laboratory tests.

31 August 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
EKEnos C. Kline
Enos C. Kline
NPNuttada Panpradist
Nuttada Panpradist
IHIan T. Hull
Ian T. Hull
QWQin Wang
Qin Wang
AOAmy K. Oreskovic
Amy K. Oreskovic
BLBarry Lutz
Barry Lutz
The COVID-19 pandemic has had tremendous impact, and the ability to perform molecular diagnostics in resource limited settings has emerged as a key resource for mitigating spread of the disease. One challenge in COVID-19 diagnosis, as well as other viruses, is ongoing mutation that can allow viruses to evade detection by diagnostic tests.

1 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
QWQin Wang
Qin Wang
EKEnos C. Kline
Enos C. Kline
SGShane D. Gilligan-Steinberg
Shane D. Gilligan-Steinberg
JLJames J. Lai
James J. Lai
IHIan T. Hull
Ian T. Hull
BLBarry Lutz
Barry Lutz
Pathogens encapsulate or encode their own suite of enzymes to facilitate replication in the host. The pathogen-derived enzymes possess specialized activities that are essential for pathogen replication and have naturally been candidates for drug targets. Phenotypic assays detecting the activities of pathogen-derived enzymes and characterizing their inhibition under drugs offer an opportunity for pathogen detection, drug resistance testing for individual patients, and as a research tool for new drug development. Here, we used HIV as an example to develop assays targeting the reverse transcriptase (RT) enzyme encapsulated in HIV for sensitive detection and phenotypic characterization, with the potential for point-of-care (POC) applications. Specifically, we targeted the complementary (cDNA) generation activity of the HIV RT enzyme by adding engineered RNA as substrates for HIV RT enzyme to generate cDNA products, followed by cDNA amplification and detection facilitated by loop-mediated isothermal amplification (LAMP) or CRISPR-Cas systems. To guide the assay design, we first used qPCR to characterize the cDNA generation activity of HIV RT enzyme. In the LAMP-mediated Product-Amplified RT activity assay (LamPART), the cDNA generation and LAMP amplification were combined into one pot with novel assay designs. When coupled with direct immunocapture of HIV RT enzyme for sample preparation and endpoint lateral flow assays for detection, LamPART detected as few as 20 copies of HIV RT enzyme spiked into 25μL plasma (fingerstick volume), equivalent to a single virion. In the Cas-mediated Product-Amplified RT activity assay (CasPART), we tailored the substrate design to achieve a LoD of 2e4 copies (1.67fM) of HIV RT enzyme. Furthermore, with its phenotypic characterization capability, CasPART was used to characterize the inhibition of HIV RT enzyme under antiretroviral drugs and differentiate between wild-type and mutant HIV RT enzyme for potential phenotypic drug resistance testing. Moreover, the CasPART assay can be readily adapted to target the activity of other pathogen-derived enzymes. As a proof-of-concept, we successfully adapted CasPART to detect HIV integrase with a sensitivity of 83nM. We anticipate the developed approach of detecting enzyme activity with product amplification has the potential for a wide range of pathogen detection and phenotypic characterization.

15 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SHSayamon Hongjaisee
Sayamon Hongjaisee
NKNang Kham-Kjing
Nang Kham-Kjing
PMPiyagorn Musikul
Piyagorn Musikul
WDWannaporn Daengkaokhew
Wannaporn Daengkaokhew
NKNuntita Kongson
Nuntita Kongson
WKWoottichai Khamduang
Woottichai Khamduang
Since SARS-CoV-2 is a highly transmissible virus, a rapid and accurate diagnostic method is necessary to prevent virus spread. We aimed to develop and evaluate a new rapid colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2 detection in a single closed-tube. Nasopharyngeal and throat swabs collected from at-risk individuals testing for SARS-CoV-2 were used to assess the sensitivity and specificity of a new RT-LAMP assay against a commercial qRT-PCR assay. Total RNA extracts were submitted to the RT-LAMP reaction under optimal conditions and amplified at 65°C for 30 minutes using three sets of specific primers targeting the nucleocapsid gene. The reaction was detected using two different indicator dyes, hydroxynaphthol blue (HNB) and cresol red. A total of 82 samples were used for detection with HNB and 94 samples with cresol red, and results were compared with the qRT-PCR assay. The sensitivity of the RT-LAMP-based HNB assay was 92.1% and the specificity was 93.2%. The sensitivity of the RT-LAMP-based cresol red assay was 80.3%, and the specificity was 97%. This colorimetric feature makes this assay highly accessible, low-cost, and user-friendly, which can be deployed for massive scale-up and rapid diagnosis of SARS-CoV-2 infection, particularly in low-resource settings.

13 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
NPNuttada Panpradist
Nuttada Panpradist
RARobert G. Atkinson
Robert G. Atkinson
MRMichael Roller
Michael Roller
EKEnos Kline
Enos Kline
QWQin Wang
Qin Wang
PDPaul K Drain
Paul K Drain
RNA amplification tests allow sensitive detection of SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed “Harmony COVID-19”, a point-of-care test using inexpensive consumables, ready-to-use reagents, and a simple device that processes up to 4 samples simultaneously. Our lyophilized reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can detect as little as 15 SARS-CoV-2 RNA copies per reaction, and it can report as early as 17 min for samples with high viral load (2 x 10 5 RNA copies per reaction). Analysis of RNA extracted from clinical nasal specimens (n = 101) showed 95% concordance with RT-PCR, including 100% specificity in specimens positive for other viruses and bacteria. Analysis of contrived samples in the nasal matrix showed detection of 92% or 100% in samples with ≥20 or ≥100 particles per reaction, respectively. Usability testing showed 95% accuracy by healthcare workers operating the test for the first time. ONE SENTENCE SUMMARY: Harmony COVID-19: point-of-care SARS-CoV-2 RNA detection

2 February 2025 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
EKEnos C. Kline
Enos C. Kline
RDRose Duong
Rose Duong
QWQin Wang
Qin Wang
BLBarry Lutz
Barry Lutz
Phage-like particles (PLPs) are fabricated self-assembling nanoparticles derived from the structural elements of bacteriophages. These particles have biotechnological utility because of the ability to easily modify surface chemistry and compartmentalize nucleic acids or other materials. A consequential implementation of PLPs in diagnostics is as process controls in nucleic acid amplification tests, where control RNAs are packaged within the protein capsid and protected from degradation by RNases in the sample matrix. Key developments in PLP controls have enhanced the packing efficiency of RNAs into particles, reduced the complexity of their plasmid expression systems, and shifted purification from ultracentrifugation to affinity chromatography, producing progressively greater yields with higher purity. Expanding on prior improvements, this study establishes a revised set of plasmid vectors for Emesvirus zinderi (MS2) derived PLPs that streamline vector manipulations for rapid prototyping of new particles, provide validation of an alternative affinity tag for purification, and contributes a high-throughput low-volume spin column purification strategy. These advancements are combined with a novel internal fusion site in MS2 maturation protein A, a passive element of the MS2 capsid in prior PLP designs, that is capable of displaying polypeptides on the particles' surface. The functionality of the chimeric maturation protein's surface display is verified with an affinity tag fusion and subsequent purification. This advancement increases the number of available peptide display sites for the MS2 PLP platform with wide-ranging implications for future applications.